Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573328 | 0.87 | ALDH1A1 (0.59) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1575047 | 0.87 | CYP2D6 (0.55) | ALDH1A1CYP2D6NPC1PAX8CYP1A2 | |
| SCHEMBL1575149 | 0.87 | CACNA1H (0.46) | PAX8 | |
| SCHEMBL1574854 | 0.86 | GRIN2B (0.59) | POLBMAPTTRPV1SMN1; SMN2 | |
| SCHEMBL1575244 | 0.86 | ALDH1A1 (0.58) | ALDH1A1NPC1ALOX15MAPTSMN1; SMN2 | |
| SCHEMBL1574679 | 0.85 | PAX8 (0.49) | ALDH1A1CYP2D6NPC1PAX8CYP1A2 | |
| SCHEMBL1574936 | 0.85 | KMT2A (0.52) | ALDH1A1NPC1POLBMAPTSMN1; SMN2 | |
| SCHEMBL1574702 | 0.85 | GRIN2B (0.52) | ALDH1A1NPC1CYP2C19CYP2C9POLB | |
| SCHEMBL1574799 | 0.84 | MAPT (0.59) | ALDH1A1CYP2D6CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL1575200 | 0.84 | CYP2D6 (0.52) | ALDH1A1CYP2D6NPC1PAX8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | ALDH1A1 1445/4885CYP2D6 354/4885NPC1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.